NeoGenomics has extended its oncology testing portfolio to the Epic Aura electronic health record platform, enabling community oncology practices to order solid‑tumor and hematologic malignancy tests directly within their existing workflow and view results in the same system used for patient care.
The integration removes a key barrier to adoption by embedding NeoGenomics’ testing services into the daily clinical workflow. Early estimates suggest that the streamlined ordering and reporting process could lift test volumes by 20‑30% at each site, a boost that would accelerate the company’s move toward higher‑value next‑generation sequencing and molecular residual disease testing.
CEO Tony Zook said, "Clinicians need timely access to the right diagnostics within the systems they already rely on. Successfully integrating with Epic enables us to bring our testing capabilities directly into everyday care delivery." The move supports NeoGenomics’ strategy to deepen its reach in the precision‑oncology market, where it already accounts for a growing share of community‑based cancer care.
Financially, NeoGenomics reported Q4 2025 revenue of $190.2 million, up 10.6% year‑over‑year, and positive adjusted EBITDA of $13 million. For FY2026 the company has guided revenue of $793–$801 million and a net loss of $63–$50 million, reflecting continued investment in its digital health platform while maintaining a positive operating trajectory. NGS volumes grew 23% in Q4 2025 and 22% for the full year, underscoring the shift toward higher‑margin testing services.
The Epic Aura integration strengthens NeoGenomics’ competitive moat by improving accessibility for community oncology providers, a segment that delivers roughly 80% of cancer care. While the company’s Altman Z‑Score indicates a distress zone, the positive EBITDA trend and the expansion of its digital footprint suggest that the firm is positioning itself for sustained growth in a market that increasingly rewards seamless data integration and high‑value testing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.